Table of Content
1 EXECUTIVE SUMMARY
2 MARKET DEFINITION, SCOPE AND SEGMENTATION
2.1 PRODUCTS INCLUDED AND EXCLUDED
2.2 SEGMENTATION AXES AND THEIR VALUES
2.3 COUNTRIES AND REGIONAL GROUPINGS
2.4 PRODUCTS APPEARING IN BOTH REPORTS
3 RESEARCH METHODOLOGY AND DATA SOURCES
3.1 SOURCE HIERARCHY AND WHAT EACH SOURCE COVERS
3.2 REPORTED, DERIVED AND ESTIMATED: EX-U.S. AND EX-INDIA
3.3 COVERAGE MAP: EX-U.S. AND EX-INDIA
3.4 ASSUMPTIONS AND LIMITATIONS
4 INSULIN MARKET OVERVIEW
5 MARKET DYNAMICS
5.1 DRIVERS
5.1.1 ANALOGUE CONVERSION CARRYING THE VALUE EVEN WHERE THE VIAL COUNT BARELY MOVES
5.1.2 THREE MANUFACTURERS, AND A MARKET WHOSE PRICE MOVES AT NAMED MOMENTS
5.1.3 A PATIENT BASE GROWING FASTEST WHERE THE VALUE PER PATIENT IS LOWEST
5.1.4 AN INSTITUTION PAYS FOR ALMOST ALL OF IT, SO DEMAND DOES NOT WAIT FOR THE PATIENT
5.1.5 BASAL INSULIN AS THE ANCHOR CATEGORY, AND THE GROUND EVERY NEW PRODUCT IS LAUNCHED INTO
5.2 RESTRAINTS
5.2.1 PROCUREMENT THAT RESETS THE PRICE OF A MOLECULE IN ONE STEP
5.2.2 GLP-1 RECEPTOR AGONISTS TAKING THE PATIENT BEFORE INSULIN IS STARTED
5.2.3 BIOSIMILAR ENTRY INTO THE MOLECULES THAT CARRY THE MOST VALUE
5.2.4 THE DEVICE DECIDES WHAT CAN BE SOLD WHERE, AND THE COLD CHAIN DECIDES WHAT SURVIVES THE JOURNEY
5.3 OPPORTUNITIES
5.3.1 ONCE-WEEKLY BASAL INSULIN, AND A SCOPE THAT CONTAINS ITS BEST MARKETS
5.3.2 EGYPT, TURKEY AND INDONESIA: PATIENTS ALREADY PRESENT, VALUE NOT YET ATTACHED
5.3.3 BIOSIMILAR INSULIN AS A ROUTE INTO MARKETS THE ORIGINATORS PRICE OUT OF
5.3.4 PREMIX, THE CATEGORY THE EMERGING MARKETS ACTUALLY BUY AND THE NEWEST PRODUCTS IGNORE
5.4 CHALLENGES
5.4.1 A MARKET WHOSE TRUE SIZE IS KNOWABLE ONLY THROUGH THREE COMPANIES' ACCOUNTS
5.4.2 OBSERVATION THAT REACHES FOUR COUNTRIES OF TWENTY-ONE, AND ONLY ONE CHANNEL IN MOST OF THEM
5.4.3 CURRENCY MOVEMENT THAT CAN BE MISTAKEN FOR MARKET MOVEMENT
5.4.4 ONE OF THE THREE COMPANIES THAT MAKE THIS MARKET PUBLISHES NOTHING ABOUT IT
5.5 EMERGING TRENDS IN THE INDUSTRY
5.5.1 THE DEVICE, NOT THE MOLECULE, IS WHERE THE REMAINING PREMIUM SITS
5.5.2 VOLUME-BASED PROCUREMENT SPREADING FROM CHINA OUTWARDS
5.5.3 FIXED-RATIO AND WEEKLY COMBINATIONS REORGANISING THE BASAL CATEGORY
5.5.4 DOMESTIC MANUFACTURERS TAKING THE LARGEST SINGLE MARKET ON LOCAL COST
5.5.5 BUYERS PUBLISHING WHAT THEY PAID, WHICH TURNS A PRICE INTO A PUBLIC REFERENCE
5.6 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES
5.7 PORTER'S FIVE FORCES ANALYSIS
5.8 PESTEL ANALYSIS
5.9 SWOT ANALYSIS
6 INSULIN MARKET, BY MOLECULE, 2018–2033 (USD MILLION)
6.1 OVERVIEW
6.2 HUMAN INSULIN
6.3 INSULIN ASPART
6.4 INSULIN GLARGINE
6.5 INSULIN LISPRO
6.6 INSULIN DEGLUDEC
6.7 INSULIN DEGLUDEC; INSULIN ASPART
6.8 INSULIN DEGLUDEC; LIRAGLUTIDE
6.9 INSULIN DETEMIR
6.1 INSULIN GLARGINE; LIXISENATIDE
6.11 INSULIN GLULISINE
6.12 INSULIN ICODEC
6.13 INSULIN ICODEC; SEMAGLUTIDE
7 INSULIN MARKET, BY INSULIN CLASS, 2018–2033 (USD MILLION)
7.1 OVERVIEW
7.2 HUMAN INSULIN
7.3 ANALOGUE
8 INSULIN MARKET, BY THERAPEUTIC CATEGORY, 2018–2033 (USD MILLION)
8.1 OVERVIEW
8.2 BASAL
8.3 PRANDIAL
8.4 PREMIX
8.5 FIXED COMBINATION WITH GLP-1
9 INSULIN MARKET, BY PRESENTATION AND DEVICE, 2018–2033 (USD MILLION)
9.1 OVERVIEW
9.2 VIAL
9.2.1 HUMAN INSULIN
9.2.2 INSULIN ASPART
9.2.3 INSULIN GLARGINE
9.2.4 INSULIN LISPRO
9.2.5 INSULIN DEGLUDEC
9.2.6 INSULIN DEGLUDEC; INSULIN ASPART
9.2.7 INSULIN DEGLUDEC; LIRAGLUTIDE
9.2.8 INSULIN DETEMIR
9.2.9 INSULIN GLARGINE; LIXISENATIDE
9.2.10 INSULIN GLULISINE
9.2.11 INSULIN ICODEC
9.2.12 INSULIN ICODEC; SEMAGLUTIDE
9.3 CARTRIDGE
9.3.1 HUMAN INSULIN
9.3.2 INSULIN ASPART
9.3.3 INSULIN GLARGINE
9.3.4 INSULIN LISPRO
9.3.5 INSULIN DEGLUDEC
9.3.6 INSULIN DEGLUDEC; INSULIN ASPART
9.3.7 INSULIN DEGLUDEC; LIRAGLUTIDE
9.3.8 INSULIN DETEMIR
9.3.9 INSULIN GLARGINE; LIXISENATIDE
9.3.10 INSULIN GLULISINE
9.3.11 INSULIN ICODEC
9.3.12 INSULIN ICODEC; SEMAGLUTIDE
9.4 REUSABLE-PEN CARTRIDGE
9.4.1 HUMAN INSULIN
9.4.2 INSULIN ASPART
9.4.3 INSULIN GLARGINE
9.4.4 INSULIN LISPRO
9.4.5 INSULIN DEGLUDEC
9.4.6 INSULIN DEGLUDEC; INSULIN ASPART
9.4.7 INSULIN DEGLUDEC; LIRAGLUTIDE
9.4.8 INSULIN DETEMIR
9.4.9 INSULIN GLARGINE; LIXISENATIDE
9.4.10 INSULIN GLULISINE
9.4.11 INSULIN ICODEC
9.4.12 INSULIN ICODEC; SEMAGLUTIDE
9.5 DISPOSABLE PEN
9.5.1 HUMAN INSULIN
9.5.2 INSULIN ASPART
9.5.3 INSULIN GLARGINE
9.5.4 INSULIN LISPRO
9.5.5 INSULIN DEGLUDEC
9.5.6 INSULIN DEGLUDEC; INSULIN ASPART
9.5.7 INSULIN DEGLUDEC; LIRAGLUTIDE
9.5.8 INSULIN DETEMIR
9.5.9 INSULIN GLARGINE; LIXISENATIDE
9.5.10 INSULIN GLULISINE
9.5.11 INSULIN ICODEC
9.5.12 INSULIN ICODEC; SEMAGLUTIDE
9.6 OTHER
9.6.1 HUMAN INSULIN
9.6.2 INSULIN ASPART
9.6.3 INSULIN GLARGINE
9.6.4 INSULIN LISPRO
9.6.5 INSULIN DEGLUDEC
9.6.6 INSULIN DEGLUDEC; INSULIN ASPART
9.6.7 INSULIN DEGLUDEC; LIRAGLUTIDE
9.6.8 INSULIN DETEMIR
9.6.9 INSULIN GLARGINE; LIXISENATIDE
9.6.10 INSULIN GLULISINE
9.6.11 INSULIN ICODEC
9.6.12 INSULIN ICODEC; SEMAGLUTIDE
10 INSULIN MARKET, BY CHANNEL, 2018–2033 (USD MILLION)
10.1 OVERVIEW
10.2 PUBLIC TENDER
10.2.1 BY MOLECULE
10.2.2 BY PRESENTATION / DEVICE
10.3 HOSPITAL
10.3.1 BY MOLECULE
10.3.2 BY PRESENTATION / DEVICE
10.4 RETAIL PHARMACY
10.4.1 BY MOLECULE
10.4.2 BY PRESENTATION / DEVICE
10.5 PRIVATE MARKET
10.5.1 BY MOLECULE
10.5.2 BY PRESENTATION / DEVICE
11 INSULIN MARKET, BY GEOGRAPHY, 2018–2033 (USD MILLION)
11.1 OVERVIEW
11.2 GLOBAL
11.2.1 EU-5
11.2.1.1 GERMANY
11.2.1.2 FRANCE
11.2.1.3 ITALY
11.2.1.4 SPAIN
11.2.1.5 UNITED KINGDOM
11.2.2 LATIN AMERICA
11.2.2.1 BRAZIL
11.2.2.2 MEXICO
11.2.2.3 ARGENTINA
11.2.2.4 COLOMBIA
11.2.2.5 CHILE
11.2.3 CHINA
11.2.3.1 CHINA
11.2.4 SOUTHEAST ASIA
11.2.4.1 INDONESIA
11.2.4.2 THAILAND
11.2.4.3 VIETNAM
11.2.4.4 PHILIPPINES
11.2.4.5 MALAYSIA
11.2.4.6 SINGAPORE
11.2.5 MENA
11.2.5.1 SAUDI ARABIA
11.2.5.2 UNITED ARAB EMIRATES
11.2.5.3 EGYPT
11.2.5.4 TURKEY
12 PRICING ANALYSIS
12.1 PRICE BY TYPE: LIST, EX-FACTORY, REIMBURSED, TENDER, RETAIL
12.2 PRICE PER STANDARD UNIT BY COUNTRY
12.3 PRICE MOVEMENT, 2018-2025
13 TENDER AND PUBLIC PROCUREMENT ANALYSIS
14 PRODUCT AND MOLECULE LANDSCAPE
14.1 MARKETED AGAINST REGISTERED-NOT-MARKETED
15 REGULATORY FRAMEWORK AND APPROVAL PATHWAYS
16 DEVICE AND PRESENTATION ANALYSIS
16.1 VIAL, CARTRIDGE, REUSABLE-PEN CARTRIDGE AND DISPOSABLE PEN, REPORTED SEPARATELY
16.2 DEVICE MIX BY COUNTRY AND BY COMPANY
16.3 PRICE PER UNIT BY PRESENTATION
17 COMPETITIVE LANDSCAPE
17.1 COMPANY RANKING BY COUNTRY AND REGION
18 COMPANY PROFILES
18.1 BIOCON BIOLOGICS
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 M&A
18.1.5 OTHERS
18.1.6 PRODUCT PORTFOLIO
18.1.7 RECENT DEVELOPMENTS
18.2 NOVO NORDISK
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 MAJOR DEALS
18.2.5 INNOVATIONS
18.2.6 PRODUCT LAUNCHES
18.2.7 OTHERS
18.2.8 PRODUCT PORTFOLIO
18.2.9 RECENT DEVELOPMENTS
18.3 ELI LILLY
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT LAUNCHES
18.3.5 OTHERS
18.3.6 PRODUCT PORTFOLIO
18.3.7 RECENT DEVELOPMENTS
18.4 SANOFI
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 COLLABORATION
18.4.5 PRODUCT LAUNCHES
18.4.6 OTHERS
18.4.7 PRODUCT PORTFOLIO
18.4.8 RECENT DEVELOPMENTS
18.5 GAN & LEE
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCTION CAPACITY EXPANSION
18.5.5 OTHERS
18.5.6 PRODUCT PORTFOLIO
18.5.7 RECENT DEVELOPMENTS
18.6 BIOMM
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 COLLABORATION
18.6.5 OTHERS
18.6.6 PRODUCT PORTFOLIO
18.6.7 RECENT DEVELOPMENTS
18.7 WOCKHARDT
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCTION CAPACITY EXPANSION
18.7.5 PRODUCT LAUNCHES
18.7.6 OTHERS
18.7.7 PRODUCT PORTFOLIO
18.7.8 RECENT DEVELOPMENTS
18.8 JULPHAR
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCTION CAPACITY EXPANSION
18.8.5 PRODUCT LAUNCHES
18.8.6 OTHERS
18.8.7 PRODUCT PORTFOLIO
18.8.8 RECENT DEVELOPMENTS
18.9 TONGHUA DONGBAO
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 INNOVATIONS
18.9.5 PRODUCT LAUNCHES
18.9.6 OTHERS
18.9.7 PRODUCT PORTFOLIO
18.9.8 RECENT DEVELOPMENTS
18.1 SEDICO
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCTION CAPACITY EXPANSION
18.10.5 OTHERS
18.10.6 PRODUCT PORTFOLIO
18.10.7 RECENT DEVELOPMENTS
19 COMMERCIAL PRESENCE AND ROUTE TO MARKET
20 COUNTRY DEEP-DIVES
21 DELIVERABLES, SOURCES AND LIMITATIONS
List of Table
TABLE 1 PESTEL ANALYSIS
TABLE 2 INSULIN MARKET, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 3 INSULIN MARKET, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 4 INSULIN MARKET, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 5 INSULIN MARKET, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 6 INSULIN MARKET, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 7 INSULIN MARKET, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 8 INSULIN MARKET, BY PRESENTATION AND DEVICE, 2018-2025 (USD MILLION)
TABLE 9 INSULIN MARKET, BY PRESENTATION AND DEVICE, 2026-2033 (USD MILLION)
TABLE 10 VIAL, BY TYPE, 2018-2025 (USD MILLION)
TABLE 11 VIAL, BY TYPE, 2026-2033 (USD MILLION)
TABLE 12 CARTRIDGE, BY TYPE, 2018-2025 (USD MILLION)
TABLE 13 CARTRIDGE, BY TYPE, 2026-2033 (USD MILLION)
TABLE 14 REUSABLE-PEN CARTRIDGE, BY TYPE, 2018-2025 (USD MILLION)
TABLE 15 REUSABLE-PEN CARTRIDGE, BY TYPE, 2026-2033 (USD MILLION)
TABLE 16 DISPOSABLE PEN, BY TYPE, 2018-2025 (USD MILLION)
TABLE 17 DISPOSABLE PEN, BY TYPE, 2026-2033 (USD MILLION)
TABLE 18 OTHER, BY TYPE, 2018-2025 (USD MILLION)
TABLE 19 OTHER, BY TYPE, 2026-2033 (USD MILLION)
TABLE 20 INSULIN MARKET, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 21 INSULIN MARKET, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 22 PUBLIC TENDER, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 23 PUBLIC TENDER, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 24 PUBLIC TENDER, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 25 PUBLIC TENDER, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 26 HOSPITAL, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 27 HOSPITAL, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 28 HOSPITAL, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 29 HOSPITAL, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 30 RETAIL PHARMACY, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 31 RETAIL PHARMACY, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 32 RETAIL PHARMACY, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 33 RETAIL PHARMACY, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 34 PRIVATE MARKET, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 35 PRIVATE MARKET, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 36 PRIVATE MARKET, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 37 PRIVATE MARKET, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 38 INSULIN MARKET, BY GEOGRAPHY, 2018-2025 (USD MILLION)
TABLE 39 INSULIN MARKET, BY GEOGRAPHY, 2026-2033 (USD MILLION)
TABLE 40 EU-5, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 41 EU-5, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 42 EU-5, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 43 EU-5, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 44 EU-5, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 45 EU-5, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 46 EU-5, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 47 EU-5, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 48 EU-5, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 49 EU-5, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 50 EU-5, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 51 EU-5, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 52 GERMANY, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 53 GERMANY, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 54 GERMANY, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 55 GERMANY, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 56 GERMANY, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 57 GERMANY, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 58 GERMANY, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 59 GERMANY, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 60 GERMANY, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 61 GERMANY, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 62 FRANCE, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 63 FRANCE, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 64 FRANCE, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 65 FRANCE, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 66 FRANCE, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 67 FRANCE, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 68 FRANCE, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 69 FRANCE, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 70 FRANCE, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 71 FRANCE, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 72 ITALY, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 73 ITALY, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 74 ITALY, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 75 ITALY, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 76 ITALY, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 77 ITALY, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 78 ITALY, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 79 ITALY, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 80 ITALY, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 81 ITALY, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 82 SPAIN, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 83 SPAIN, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 84 SPAIN, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 85 SPAIN, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 86 SPAIN, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 87 SPAIN, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 88 SPAIN, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 89 SPAIN, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 90 SPAIN, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 91 SPAIN, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 92 UNITED KINGDOM, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 93 UNITED KINGDOM, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 94 UNITED KINGDOM, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 95 UNITED KINGDOM, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 96 UNITED KINGDOM, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 97 UNITED KINGDOM, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 98 UNITED KINGDOM, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 99 UNITED KINGDOM, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 100 UNITED KINGDOM, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 101 UNITED KINGDOM, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 102 LATIN AMERICA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 103 LATIN AMERICA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 104 LATIN AMERICA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 105 LATIN AMERICA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 106 LATIN AMERICA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 107 LATIN AMERICA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 108 LATIN AMERICA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 109 LATIN AMERICA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 110 LATIN AMERICA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 111 LATIN AMERICA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 112 LATIN AMERICA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 113 LATIN AMERICA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 114 BRAZIL, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 115 BRAZIL, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 116 BRAZIL, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 117 BRAZIL, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 118 BRAZIL, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 119 BRAZIL, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 120 BRAZIL, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 121 BRAZIL, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 122 BRAZIL, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 123 BRAZIL, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 124 MEXICO, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 125 MEXICO, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 126 MEXICO, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 127 MEXICO, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 128 MEXICO, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 129 MEXICO, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 130 MEXICO, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 131 MEXICO, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 132 MEXICO, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 133 MEXICO, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 134 ARGENTINA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 135 ARGENTINA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 136 ARGENTINA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 137 ARGENTINA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 138 ARGENTINA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 139 ARGENTINA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 140 ARGENTINA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 141 ARGENTINA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 142 ARGENTINA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 143 ARGENTINA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 144 COLOMBIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 145 COLOMBIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 146 COLOMBIA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 147 COLOMBIA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 148 COLOMBIA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 149 COLOMBIA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 150 COLOMBIA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 151 COLOMBIA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 152 COLOMBIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 153 COLOMBIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 154 CHILE, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 155 CHILE, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 156 CHILE, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 157 CHILE, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 158 CHILE, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 159 CHILE, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 160 CHILE, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 161 CHILE, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 162 CHILE, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 163 CHILE, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 164 CHINA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 165 CHINA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 166 CHINA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 167 CHINA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 168 CHINA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 169 CHINA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 170 CHINA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 171 CHINA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 172 CHINA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 173 CHINA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 174 CHINA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 175 CHINA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 176 CHINA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 177 CHINA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 178 CHINA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 179 CHINA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 180 CHINA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 181 CHINA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 182 CHINA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 183 CHINA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 184 CHINA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 185 CHINA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 186 SOUTHEAST ASIA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 187 SOUTHEAST ASIA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 188 SOUTHEAST ASIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 189 SOUTHEAST ASIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 190 SOUTHEAST ASIA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 191 SOUTHEAST ASIA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 192 SOUTHEAST ASIA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 193 SOUTHEAST ASIA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 194 SOUTHEAST ASIA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 195 SOUTHEAST ASIA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 196 SOUTHEAST ASIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 197 SOUTHEAST ASIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 198 INDONESIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 199 INDONESIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 200 INDONESIA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 201 INDONESIA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 202 INDONESIA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 203 INDONESIA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 204 INDONESIA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 205 INDONESIA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 206 INDONESIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 207 INDONESIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 208 THAILAND, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 209 THAILAND, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 210 THAILAND, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 211 THAILAND, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 212 THAILAND, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 213 THAILAND, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 214 THAILAND, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 215 THAILAND, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 216 THAILAND, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 217 THAILAND, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 218 VIETNAM, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 219 VIETNAM, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 220 VIETNAM, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 221 VIETNAM, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 222 VIETNAM, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 223 VIETNAM, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 224 VIETNAM, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 225 VIETNAM, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 226 VIETNAM, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 227 VIETNAM, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 228 PHILIPPINES, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 229 PHILIPPINES, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 230 PHILIPPINES, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 231 PHILIPPINES, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 232 PHILIPPINES, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 233 PHILIPPINES, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 234 PHILIPPINES, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 235 PHILIPPINES, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 236 PHILIPPINES, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 237 PHILIPPINES, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 238 MALAYSIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 239 MALAYSIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 240 MALAYSIA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 241 MALAYSIA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 242 MALAYSIA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 243 MALAYSIA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 244 MALAYSIA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 245 MALAYSIA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 246 MALAYSIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 247 MALAYSIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 248 SINGAPORE, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 249 SINGAPORE, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 250 SINGAPORE, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 251 SINGAPORE, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 252 SINGAPORE, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 253 SINGAPORE, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 254 SINGAPORE, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 255 SINGAPORE, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 256 SINGAPORE, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 257 SINGAPORE, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 258 MENA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 259 MENA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 260 MENA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 261 MENA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 262 MENA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 263 MENA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 264 MENA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 265 MENA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 266 MENA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 267 MENA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 268 MENA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 269 MENA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 270 SAUDI ARABIA, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 271 SAUDI ARABIA, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 272 SAUDI ARABIA, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 273 SAUDI ARABIA, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 274 SAUDI ARABIA, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 275 SAUDI ARABIA, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 276 SAUDI ARABIA, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 277 SAUDI ARABIA, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 278 SAUDI ARABIA, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 279 SAUDI ARABIA, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 280 UNITED ARAB EMIRATES, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 281 UNITED ARAB EMIRATES, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 282 UNITED ARAB EMIRATES, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 283 UNITED ARAB EMIRATES, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 284 UNITED ARAB EMIRATES, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 285 UNITED ARAB EMIRATES, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 286 UNITED ARAB EMIRATES, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 287 UNITED ARAB EMIRATES, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 288 UNITED ARAB EMIRATES, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 289 UNITED ARAB EMIRATES, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 290 EGYPT, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 291 EGYPT, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 292 EGYPT, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 293 EGYPT, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 294 EGYPT, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 295 EGYPT, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 296 EGYPT, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 297 EGYPT, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 298 EGYPT, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 299 EGYPT, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 300 TURKEY, BY MOLECULE, 2018-2025 (USD MILLION)
TABLE 301 TURKEY, BY MOLECULE, 2026-2033 (USD MILLION)
TABLE 302 TURKEY, BY INSULIN CLASS, 2018-2025 (USD MILLION)
TABLE 303 TURKEY, BY INSULIN CLASS, 2026-2033 (USD MILLION)
TABLE 304 TURKEY, BY THERAPEUTIC CATEGORY, 2018-2025 (USD MILLION)
TABLE 305 TURKEY, BY THERAPEUTIC CATEGORY, 2026-2033 (USD MILLION)
TABLE 306 TURKEY, BY PRESENTATION / DEVICE, 2018-2025 (USD MILLION)
TABLE 307 TURKEY, BY PRESENTATION / DEVICE, 2026-2033 (USD MILLION)
TABLE 308 TURKEY, BY CHANNEL, 2018-2025 (USD MILLION)
TABLE 309 TURKEY, BY CHANNEL, 2026-2033 (USD MILLION)
TABLE 310 PRICE BY TYPE: LIST, EX-FACTORY, REIMBURSED, TENDER, RETAIL
TABLE 311 PRICE PER STANDARD UNIT BY COUNTRY
TABLE 312 OBSERVED MONTHLY PURCHASING RECORD, AS PUBLISHED
TABLE 313 PRICE IN LOCAL CURRENCY AGAINST USD, WITH STATED RATE
TABLE 314 APPROVAL AND LAUNCH DATE BY COUNTRY
TABLE 315 MARKETED AGAINST REGISTERED-NOT-MARKETED
TABLE 316 APPROVAL PATHWAY AND GOVERNING BODY, BY COUNTRY
TABLE 317 WHO DECIDES WHAT A BIOSIMILAR IS PAID, AND HOW
TABLE 318 VIAL, CARTRIDGE, REUSABLE-PEN CARTRIDGE AND DISPOSABLE PEN, REPORTED SEPARATELY
TABLE 319 DEVICE MIX BY COUNTRY AND BY COMPANY
TABLE 320 PRICE PER UNIT BY PRESENTATION
TABLE 321 COMPANY SHARE BY VALUE AND VOLUME, 2025
TABLE 322 EU-5: COMPANY SHARE BY VOLUME, 2025
TABLE 323 LATIN AMERICA: COMPANY SHARE BY VOLUME, 2025
TABLE 324 SOUTH-EAST ASIA: COMPANY SHARE BY VOLUME, 2025
TABLE 325 MIDDLE EAST AND NORTH AFRICA: COMPANY SHARE BY VOLUME, 2025
TABLE 326 CHINA: COMPANY SHARE BY VOLUME, 2025
TABLE 327 EU-5: COMPANY SHARE BY VALUE, 2025
TABLE 328 LATIN AMERICA: COMPANY SHARE BY VALUE, 2025
TABLE 329 SOUTH-EAST ASIA: COMPANY SHARE BY VALUE, 2025
TABLE 330 MIDDLE EAST AND NORTH AFRICA: COMPANY SHARE BY VALUE, 2025
TABLE 331 CHINA: COMPANY SHARE BY VALUE, 2025
TABLE 332 NUMBER OF MARKETED PRODUCTS PER COMPANY
TABLE 333 SALES GROWTH BY COMPANY
TABLE 334 BIOCON BIOLOGICS: PRODUCT PORTFOLIO
TABLE 335 BIOCON BIOLOGICS: RECENT DEVELOPMENTS
TABLE 336 NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 337 NOVO NORDISK: RECENT DEVELOPMENTS
TABLE 338 ELI LILLY: PRODUCT PORTFOLIO
TABLE 339 ELI LILLY: RECENT DEVELOPMENTS
TABLE 340 SANOFI: PRODUCT PORTFOLIO
TABLE 341 SANOFI: RECENT DEVELOPMENTS
TABLE 342 GAN & LEE: PRODUCT PORTFOLIO
TABLE 343 GAN & LEE: RECENT DEVELOPMENTS
TABLE 344 BIOMM: PRODUCT PORTFOLIO
TABLE 345 BIOMM: RECENT DEVELOPMENTS
TABLE 346 WOCKHARDT: PRODUCT PORTFOLIO
TABLE 347 WOCKHARDT: RECENT DEVELOPMENTS
TABLE 348 JULPHAR: PRODUCT PORTFOLIO
TABLE 349 JULPHAR: RECENT DEVELOPMENTS
TABLE 350 TONGHUA DONGBAO: PRODUCT PORTFOLIO
TABLE 351 TONGHUA DONGBAO: RECENT DEVELOPMENTS
TABLE 352 SEDICO: PRODUCT PORTFOLIO
TABLE 353 SEDICO: RECENT DEVELOPMENTS
TABLE 354 NAMED DISTRIBUTORS AND WHOLESALERS, AND HOW MANY EACH COMPANY USES
TABLE 355 SOURCES BY CLASS, WITH COVERAGE AND DATE ACCESSED
TABLE 356 WHAT COULD NOT BE OBTAINED, AND WHY
List of Figure
FIGURE 1 EX-U.S. AND EX-INDIA INSULIN MARKET, 2018-2033 (USD MILLION)
FIGURE 2 EX-U.S. AND EX-INDIA INSULIN MARKET: SEGMENTATION AT A GLANCE, 2025
FIGURE 3 EX-U.S. AND EX-INDIA INSULIN MARKET: DRIVERS IMPACT ANALYSIS
FIGURE 4 IMPACT OF EACH FORCE, BY SEGMENT
FIGURE 5 EX-U.S. AND EX-INDIA INSULIN MARKET: PORTER'S FIVE FORCES
FIGURE 6 EX-U.S. AND EX-INDIA INSULIN MARKET: PESTLE ANALYSIS
FIGURE 7 EX-U.S. AND EX-INDIA INSULIN: SWOT ANALYSIS
FIGURE 8 SWOT: STRENGTHS AND WEAKNESSES
FIGURE 9 SWOT: OPPORTUNITIES AND THREATS
FIGURE 10 INSULIN MARKET, BY MOLECULE, 2025
FIGURE 11 EX-U.S. AND EX-INDIA INSULIN MARKET, BY MOLECULE, 2033 (USD MILLION)
FIGURE 12 INSULIN MARKET, BY INSULIN CLASS, 2025
FIGURE 13 INSULIN MARKET, BY THERAPEUTIC CATEGORY, 2025
FIGURE 14 INSULIN MARKET, BY PRESENTATION AND DEVICE, 2025
FIGURE 15 INSULIN MARKET, BY CHANNEL, 2025
FIGURE 16 INSULIN MARKET, BY GEOGRAPHY, 2025
FIGURE 17 EU-5, BY COUNTRY, 2025
FIGURE 18 LATIN AMERICA, BY COUNTRY, 2025
FIGURE 19 CHINA, BY COUNTRY, 2025
FIGURE 20 SOUTHEAST ASIA, BY COUNTRY, 2025
FIGURE 21 MENA, BY COUNTRY, 2025
FIGURE 22 BIOCON BIOLOGICS: COMPANY SNAPSHOT
FIGURE 23 NOVO NORDISK, SHARE OF THE EX-U.S. AND EX-INDIA INSULIN MARKET, 2025
FIGURE 24 NOVO NORDISK: COMPANY SNAPSHOT
FIGURE 25 ELI LILLY: COMPANY SNAPSHOT
FIGURE 26 SANOFI, SHARE OF THE EX-U.S. AND EX-INDIA INSULIN MARKET, 2025
FIGURE 27 SANOFI: COMPANY SNAPSHOT
FIGURE 28 GAN & LEE, SHARE OF THE EX-U.S. AND EX-INDIA INSULIN MARKET, 2025
FIGURE 29 GAN & LEE: COMPANY SNAPSHOT
FIGURE 30 BIOMM: COMPANY SNAPSHOT
FIGURE 31 WOCKHARDT: COMPANY SNAPSHOT
FIGURE 32 JULPHAR: COMPANY SNAPSHOT
FIGURE 33 TONGHUA DONGBAO: COMPANY SNAPSHOT
FIGURE 34 SEDICO: COMPANY SNAPSHOT
